Skip to content

Tocilizumab

Actemra, RoActemra (tocilizumab) is an antibody pharmaceutical. Tocilizumab was first approved as Actemra on 2009-01-15. It is used to treat giant cell arteritis, juvenile arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat juvenile arthritis and rheumatoid arthritis. The pharmaceutical is active against interleukin-6 receptor subunit alpha.
Trade Name RoActemra
Common Name Tocilizumab
ChEMBL ID CHEMBL1237022
Indication giant cell arteritis, juvenile arthritis, rheumatoid arthritis
Drug Class Monoclonal antibodies: humanized, immunomodulating
Tocilizumab
Get full access now